Conference Reports for NATAP

HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis December 8-12, 2013 Big Island, Hawaii Back

HepDART December 2013 Selected Slide Presentations       HepDart 2013 December, Hawaii, Selected Slide Presentations http://www.informedhorizons.com/hepdart2013/presentations.aspx   State of the Art Presentation Innovations in HCV Therapy Ira Jacobson, Weill Cornell Medical College, USA http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Jacobson_final_122713.pdf   Hepatitis C: The Tides Are Shifting   Deploying Nucleoside Therapy to Eradicate HCV John McHutchison, Gilead Sciences Inc., USA   Simeprevir Overview: From IFN-Containing to IFN-Free Regimens Gastón Picchio, Janssen R&D, USA   Daclatasvir Present and Future DAA Combinations Douglas Manion, Bristol-Myers Squibb, USA   Efficacy and Resistance Profile of the next Generation Protease Inhibitor MK5172 in IFN-free Phase 2 Studies of GT1 Infection Daria Hazuda, Merck Research Laboratories, USA   Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus Infection (HCV) Douglas Mayers, Idenix Pharmaceuticals, Inc., USA   Discovery and Development of a Second Generation Direct-Acting Antiviral Portfolio for Chronic Hepatitis C: An Update on Achillion's Protease Inhibitor (Sovaprevir), NS5A Inhibitor (3102) and Nucleotide Inhibitor (3422) Regimen Strategy David Apelian, Achillion Pharmaceuticals, Inc., USA   The Future of HCV Therapy: Patient-Tailored Treatment or One-Size Fits All? Wulf Otto Böcher, Boehringer Ingelheim Pharma GmbH & Co KG, Germany   High Sustained Virologic Response Rates with Sofosbuvir Regimens Irrespective of Ribavirin Dose Reductions Mark Sulkowski, The Johns Hopkins University School of Medicine, USA http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Sulkowski_HepDart Oral Sulkowski_9Dec13_FINAL Tuesday.pdf   Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin, in Patients with HCV Genotype-1a Infection Richard Colonno, Presidio Pharmaceuticals, USA http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Colonno.pdf   A Fixed Dose Combination of Sofosbuvir and Ledipasvir is Highly Effective in Treatment-Naïve and Treatment Experienced Genotype 1 HCV infected Patients: Results from the LONESTAR and ELECTRON Phase 2 Studies Eric Lawitz, Texas Liver Institute and University of Texas Health Science Center, USA http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Lawitz HEPDART 2013_5Dec13_to client.pdf   Simeprevir with Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 4 Infection in Treatment-Naïve or -Experienced Patients: Interim Results of a Phase III Trial Christophe Moreno, ULB Hôpital Erasme, Belgium http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Moreno_Website.pdf   Lymphomas Associated with HCV Jordan Feld, University of Toronto, Canada http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Feld_MAC NHL Lymphoma & HCV HepDart 2013.pdf   HCV and Diabetes Francesco Negro, University Hospitals of Geneva, Switzerland http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Negro HCV diabetes HepDART 2013.pdf   State of the Art Presentation Epidemiology and Outcome of Viral Hepatitis B and C in the US W. Ray Kim, Stanford University, USA http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Kim_MAC_Website.pdf   Breaking Down the Barriers to HCV Treatment among People Who Inject Drugs Jason Grebely, University of New South Wales, Australia http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Grebely HEP DART 2013_06Dec13.pdf   Special Lecture: Off Label Combinations: Collaborative versus Incestuous Donald Jensen, University of Chicago, USA http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Jensen_REVISED Off Label Combinations.pdf